Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Aspirin professional labeling

This article was originally published in The Tan Sheet

Executive Summary

Aspirin professional labeling: Aspirin Foundation of America, in a recent letter to FDA, expresses support for the agency's June 13 proposal to add an indication for the reduction of the risk of vascular mortality in patients with a suspected acute myocardial infarction in aspirin professional labeling ("The Tan Sheet" June 17, p. 3). The group also urges FDA to add the treatment of acute MI to the professional labeling section of the monograph for aspirin...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel